Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$97.33 USD

97.33
648,582

+0.07 (0.07%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Elevance Health (ELV) Tops on Q4 Earnings, Hikes Dividend

by Zacks Equity Research

Elevance Health's (ELV) fourth-quarter earnings gain on solid premiums from its Medicaid business. Management approves a quarterly dividend hike of 16%.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Lantheus Holdings (LNTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 83.92%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Lantheus Holdings (LNTH) Crossed Above the 50-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update

by Zacks Equity Research

Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.

Why You Should Hold Molina Healthcare (MOH) in Your Portfolio

by Zacks Equity Research

Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.

Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

UnitedHealth (UNH) Unit Ties Up to Boost Care in Two U.S. Regions

by Zacks Equity Research

UnitedHealth Group's (UNH) subsidiary Optum aims to advance organizational efficiencies of Owensboro Health and bring about better health outcomes in western Kentucky and southern Indiana.

Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) closed the most recent trading day at $48.48, moving -0.94% from the previous trading session.

Teladoc (TDOC) Unveils App to Simplify Whole-Person Care

by Zacks Equity Research

Teladoc Health (TDOC) launches a digital app that will provide a broad range of TDOC's services to cater to the whole-person health needs of members.

Down -8.54% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Lantheus Holdings (LNTH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Community Health (CYH) Sells Hospital, Renews Health Net Tie-Up

by Zacks Equity Research

Community Health (CYH) announces the divestiture of its West Virginia hospital and the expansion of its alliance with Health Net, thereby undertaking initiatives to boost business prospects.

Down -21.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)

by Zacks Equity Research

Lantheus Holdings (LNTH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Is Lantheus (LNTH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

3 Medical Stocks Creating Wealth Despite Macro Challenges

by Indrajit Bandyopadhyay

Here we discuss three stocks - CAH, LNTH and TMDX - that have been creating wealth for their investors in 2022 as several competitors faltered amid macro challenges. Will the trend continue?

Lantheus Holdings (LNTH) Loses 10.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Lantheus Holdings (LNTH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how RxSight, Inc. (RXST) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLY

Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 64%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges (Revised)

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Add McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.